

NOTE: This order is nonprecedential.

**United States Court of Appeals
for the Federal Circuit**

**VALEANT PHARMACEUTICALS NORTH AMERICA
LLC, VALEANT PHARMACEUTICALS IRELAND
LTD., DOW PHARMACEUTICAL SCIENCES, INC.,
KAKEN PHARMACEUTICAL CO., LTD.,**
Plaintiffs-Appellants

v.

**MYLAN PHARMACEUTICALS INC., MYLAN
LABORATORIES LTD., MYLAN INC.,**
Defendants-Appellees

2019-2402

Appeal from the United States District Court for the
District of New Jersey in No. 3:18-cv-14305-PGS-LHG,
Senior Judge Peter G. Sheridan.

ON PETITION FOR REHEARING EN BANC

Before PROST, *Chief Judge*, NEWMAN, LOURIE, DYK,
MOORE, O'MALLEY, REYNA, WALLACH, TARANTO, CHEN,
and HUGHES, *Circuit Judges*.*

PER CURIAM.

O R D E R

* Circuit Judge Stoll did not participate.

Appellants Valeant Pharmaceuticals North America LLC, Valeant Pharmaceuticals Ireland Ltd., Dow Pharmaceutical Sciences, Inc., and Kaken Pharmaceutical Co., Ltd. filed a petition for rehearing en banc. A response to the petition was invited by the court and filed by Appellees Mylan Pharmaceuticals Inc., Mylan Laboratories Ltd., and Mylan Inc. The petition was first referred as a petition for rehearing to the panel that heard the appeal, and thereafter the petition for rehearing en banc was referred to the circuit judges who are in regular active service.

Upon consideration thereof,

IT IS ORDERED THAT:

The petition for panel rehearing is denied.

The petition for rehearing en banc is denied.

The mandate of the court will issue on February 2, 2021.

FOR THE COURT

January 26, 2021
Date

/s/ Peter R. Marksteiner
Peter R. Marksteiner
Clerk of Court